Table 3.
Non-Injection Site Treatment Emergent Adverse Events Across 24 Weeks with Incidence ≥5% in One or More Groups
| Event | Buprenorphine Implants n=114 |
Placebo Implants n=54) |
Sublingual Buprenorphine n=119 |
|---|---|---|---|
| Headache | 15 (13.2) | 5 (9.3) | 19 (16.0) |
| Upper respiratory Infection | 10 (8.8) | 4 (7.4) | 11 (9.2) |
| Depression | 10 (8.8) | 3 (5.6) | 4 (3.4) |
| Insomnia | 9 (7.9) | 8 (14.8) | 16 (13.4) |
| Sore throat | 8 (7.0) | 1 (1.9) | 4 (3.4) |
| Nausea | 7 (6.1) | 1 (1.9) | 8 (6.7) |
| Vomiting | 7 (6.1) | 1 (1.9) | 5 (4.2) |
| Nasopharyngitis | 6 (5.3) | 3 (5.6) | 12 (10.1) |
| Back pain | 6 (5.3) | 3 (5.6) | 7 (5.9) |
| Limb abscess | 3 (2.6) | 4 (7.4) | 5 (4.2) |
| Hyperhidrosis | 3 (2.6) | 3 (5.6) | 2 (1.7) |
| Anxiety | 2 (1.8) | 3 (5.6) | 7 (5.9) |
| Diarrhea | 2 (1.8) | 3 (5.6) | 2 (1.7) |
| Any “severe” event | 9 (7.9) | 3 (5.6) | 14 (11.8) |
| Any “serious” event | 6 (5.3)a | 3 (5.6) | 7 (5.9) |
a
Umbilical hernia, pneumonia (n=2), breast cancer, hypotension, tooth abscess.